Respiratorius (RESP) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue was 0 KSEK; loss after financial items was 1,761 KSEK, while business development focused on finding a partner for VAL001.

• Management assessed existing funding as sufficient to continue operations through February 2027 under the adopted budget.

Financial highlights

• Q3 revenue was 0 KSEK, unchanged YoY; Q3 result after financial items was -1,761 KSEK vs -1,447 KSEK YoY.

• 9M revenue was 0 KSEK; result after financial items was -5,269 KSEK vs -5,258 KSEK in 9M 2025.

• Q3 EPS was -SEK 0.22 vs -SEK 0.18 YoY; 9M EPS was -SEK 0.67, unchanged YoY.

Outlook and guidance

• Under the adopted budget, current funding is expected to support operations through February 2027.

• The stated objective is to secure a partner agreement for VAL001; ongoing discussions include counterparties evaluating the candidate internally.